FDA to Disclose Conflict-of-Interest Information for Committees
The FDA will begin publicly disclosing all financial conflict-of-interest information for its advisory committee members, along with copies of waivers the agency grants to allow participation on the committee.
The agency will disclose the type, nature and magnitude of financial interests on its website for each advisory committee member who receives a waiver, according to a draft guidance published in the Oct. 31 Federal Register. In addition, the FDA will post its reasons for granting the waiver. Members who do not want their financial interests publicly disclosed will not participate in meetings, the agency said.